Lineage Cell Therapeutics Stock Pattern Recognition Stalled Pattern
| LCTX Stock | USD 1.61 0.03 1.90% |
| Symbol |
Recognition |
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was twelve with a total number of output elements of forty-nine. The function did not return any valid pattern recognition events for the selected time horizon. The Stalled pattern represents a weakness and consolidation and Lineage Cell Therapeutics possible reversal in trend.
Lineage Cell Technical Analysis Modules
Most technical analysis of Lineage Cell help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Lineage from various momentum indicators to cycle indicators. When you analyze Lineage charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California. Lineage Cell operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 57 people. Downside history and drawdown behavior provide context for risk expectations in Lineage Cell. Past price movements indicate comparatively limited downside dispersion. Lineage Cell has a market cap of 370.83 M, P/E of 3.62, ROE of -105.3%.
Methodology
Unless otherwise specified, financial data for Lineage Cell Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Lineage (USA Stocks:LCTX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Lineage Cell Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Lineage Cell Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardSome investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lineage Cell in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lineage Cell's short interest history, or implied volatility extrapolated from Lineage Cell options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Momentum Invested few shares | |
 | Warren Buffett Holdings Invested over 20 shares | |
 | Macroaxis Index Invested over 60 shares | |
 | Artificial Intelligence Invested few shares | |
 | Data Storage Invested few shares | |
 | Impulse Invested over 200 shares | |
 | Hedge Favorites Invested few shares | |
 | Adviser Favorites Invested few shares | |
 | Investor Favorites Invested over 20 shares | |
More Resources for Lineage Stock Analysis
A structured review of Lineage Cell Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Lineage Cell Therapeutics Stock. Highlighted below are reports that provide context for Lineage Cell Therapeutics Stock:Lineage Cell has a market cap of 370.83 M, operating margin of -99.09%, ROE of -105.3%. Correlation Analysis can help frame allocation decisions. The allocation includes a position in Lineage Cell Therapeutics inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. Analysis related to Lineage Cell should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Earnings Share -0.29 | Revenue Per Share | Quarterly Revenue Growth 1.304 | Return On Assets | Return On Equity |
Market capitalization and book value offer complementary views of Lineage Cell Therapeutics — the first driven by investor sentiment, the second by accounting standards. Lineage Cell's market capitalization is 370.83 M. With a P/B ratio of 16.83, the market values Lineage Cell well above its book equity. Enterprise value stands at 332.96 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Lineage Cell are related but not identical, and they can diverge across cycles. For Lineage Cell, key inputs include a P/E ratio of 3.62, a P/B ratio of 16.83, ROE of -105.3%, and revenue of 14.56 M. By contrast, market price reflects the level where buyers and sellers transact.